NEW YORK, Oct. 1 – Houston-based investment banking firm Sanders Morris Harris has closed its $11 million LifeSciences Opportunity Fund, which will look to invest in early- and middle-stage functional genomics and proteomics companies.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.